WELTRUZA

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
WELTRUZA
Generic name
OLANZAPINE
Manufacturer
Teva Pharmaceuticals USA, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
a23e99c7-fb76-46d2-95af-e03d5a4d1f2c
SPL ID
1c998762-8d30-4afd-b0d5-282bcaaefb8d
Version
5
Effective date
2026-10-26
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:45
Harmonized routes table
Harmonized routes
SUBCUTANEOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 8.5 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 2 · 7 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS P ost-Injection Delirium/Sedation Syndrome (PDSS): Cases of PDSS were reported following intramuscular injection of another extended-release olanzapine product. If signs or symptoms of olanzapine overdose occur, consider PDSS in the differential diagnosis. ( 5.2 ) Neuroleptic Malignant Syndrome: Immediately discontinue WELTRUZA and provide symptomatic treatment and monitoring. ( 5.4 ) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue if DRESS is suspected. ( 5.5 ) Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain. ( 5.6 ) Tardive Dyskinesia: Discontinue if clinically appropriate ( 5.7 ) Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, may occur. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic response. ( 5.8 ) Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts in patients with a history of a clinically significant low white blood cell (WBC) count. Consider discontinuation if clinically significant decline in WBC in the absence of other causative factors. ( 5.10 ) Seizures: Use cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold. ( 5.12 ) Potential for Cognitive and Motor Impairment: Use caution when operating machinery. ( 5.13 ) Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus or related conditions. ( 5.15 ) Hyperprolactinemia: May elevate prolactin levels. ( 5.16 ) Laboratory Tests: Monitor fasting blood glucose and lipid profiles at the beginning of, and periodically during, treatment. ( 5.17 ) 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs for dementia-related psychosis, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the incidence of death in drug-treated patients was about 4.5%, compared to an incidence of about 2.6% in the placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. In placebo-controlled oral olanzapine clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively). WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Indications and Usage ( 1 )] . 5.2 Post-Injection Delirium/Sedation Syndrome Post-Injection Delirium/Sedation Syndrome (PDSS) has been reported with intramuscular use of another extended-release olanzapine product and presented with signs and symptoms consistent with olanzapine overdose [ see Overdosage ( 10.1 )] . The majority of patients were hospitalized and some required supportive care, including intubation, in several cases. These reactions occurred in <0.1% of injections and in approximately 2% of patients who received injections for up to 46 months. The majority of cases of PDSS with intramuscular use of another extended-release olanzapine product have occurred within the first 3 hours after injection; however, the reactions have also occurred after 3 hours of injection. The risk of a reaction is the same at each injection, so the risk per patient is cumulative (i.e., increases with the number of injections). Following an intramuscular injection with another extended-release olanzapine product, a rapid and greater than expected increase in serum olanzapine concentration has been observed in some patients with PDSS reactions. However, the exact mechanism by which the drug was unintentionally introduced into the blood stream is not known. Healthcare professionals should consider PDSS in the differential diagnosis in the event a patient experiences the signs and symptoms of olanzapine overdose [see Overdosage ( 10.1 )] . In pre-marketing trials with WELTRUZA, there were no reported cases of PDSS. However, the risk of PDSS with WELTRUZA is currently unknown. 5.3 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia-related psychosis treated with oral risperidone, aripiprazole, or olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke compared to those treated with placebo. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning] . 5.4 Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue WELTRUZA and provide intensive symptomatic treatment and monitoring. 5.5 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with olanzapine exposure. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue WELTRUZA if DRESS is suspected [see Patient Counseling Information ( 17 )] . 5.6 Metabolic Changes Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Weight gain and changes in metabolic laboratory parameters were consistent with those expected with long-term olanzapine treatment. Olanzapine’s specific metabolic profile, based on data from oral olanzapine, is presented below. Hyperglycemia and Diabetes Mellitus Healthcare providers should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level (fasting 100-126 mg/dL, nonfasting 140-200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug [see Patient Counseling Information ( 17 )] . Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including olanzapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to fall on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics. Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of the 2 highest serum concentrations was 15.0 mg/dL. In a study of healthy volunteers, subjects who received olanzapine (N=22) for 3 weeks had a mean increase compared to baseline in fasting blood glucose of 2.3 mg/dL. Placebo-treated subjects (N=19) had a mean increase in fasting blood glucose compared to baseline of 0.34 mg/dL. Olanzapine Monotherapy in Adults In an analysis of 5 placebo-controlled adult olanzapine monotherapy studies with a median treatment duration of approximately 3 weeks, olanzapine was associated with a greater mean change in fasting glucose levels compared to placebo (2.76 mg/dL versus 0.17 mg/dL). The difference in mean changes between olanzapine and placebo was greater in patients with evidence of glucose dysregulation at baseline (patients diagnosed with diabetes mellitus or related adverse reactions, patients treated with anti-diabetic agents, patients with a baseline random glucose level ≥200 mg/dL, and/or a baseline fasting glucose level ≥126 mg/dL). Olanzapine-treated patients had a greater mean HbA 1c increase from baseline of 0.04% (median exposure 21 days), compared to a mean HbA 1c decrease of 0.06% in placebo-treated subjects (median exposure 17 days). In an analysis of 8 placebo-controlled studies (median treatment exposure 4-5 weeks), 6.1% of olanzapine-treated subjects (N=855) had treatment-emergent glycosuria compared to 2.8% of placebo-treated subjects (N=599). Table 2 shows short-term and long-term changes in fasting glucose levels from adult olanzapine monotherapy studies. Table 2: Changes in Fasting Glucose Levels from Adult Olanzapine Monotherapy Studies Up to 12 weeks exposure At least 48 weeks exposure Laboratory Analyte Category Change (at least once) from Baseline Treatment Arm N Patients N Patients Fasting Glucose Normal to High (<100 mg/dL to ≥126 mg/dL) Olanzapine 543 2.2% 345 12.8% Placebo 293 3.4% NA a NA a Borderline to High (≥100 mg/dL and <126 mg/dL to ≥126 mg/dL) Olanzapine 178 17.4% 127 26.0% Placebo 96 11.5% NA a NA a a Not Applicable The mean change in fasting glucose for patients exposed at least 48 weeks was 4.2 mg/dL (N=487). In analyses of patients who completed 9-12 months of olanzapine therapy, mean change in fasting and nonfasting glucose levels continued to increase over time. Dyslipidemia Undesirable alterations in lipids have been observed with olanzapine use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using olanzapine, is recommended [see Patient Counseling Information ( 17 )] . Clinically significant, and sometimes very high (>500 mg/dL), elevations in triglyceride levels have been observed with olanzapine use. Modest mean increases in total cholesterol have also been seen with olanzapine use. Olanzapine Monotherapy in Adults In an analysis of 5 placebo-controlled olanzapine monotherapy studies with treatment duration up to 12 weeks, olanzapine-treated patients had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 5.3 mg/dL, 3.0 mg/dL, and 20.8 mg/dL respectively compared to decreases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 6.1 mg/dL, 4.3 mg/dL, and 10.7 mg/dL for placebo-treated patients. For fasting HDL cholesterol, no clinically meaningful differences were observed between olanzapine-treated patients and placebo-treated patients. Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline, where lipid dysregulation was defined as patients diagnosed with dyslipidemia or related adverse reactions, patients treated with lipid lowering agents, or patients with high baseline lipid levels. In long-term studies (at least 48 weeks), patients had increases from baseline in mean fasting total cholesterol, LDL cholesterol, and triglycerides of 5.6 mg/dL, 2.5 mg/dL, and 18.7 mg/dL, respectively, and a mean decrease in fasting HDL cholesterol of 0.16 mg/dL. In an analysis of patients who completed 12 months of therapy, the mean nonfasting total cholesterol did not increase further after approximately 4-6 months. The proportion of patients who had changes (at least once) in total cholesterol, LDL cholesterol or triglycerides from normal or borderline to high, or changes in HDL cholesterol from normal or borderline to low, was greater in long-term studies (at least 48 weeks) as compared with short-term studies. Table 3 shows categorical changes in fasting lipids values. Table 3: Changes in Fasting Lipids Values from Adult Olanzapine Monotherapy Studies Up to 12 weeks exposure At least 48 weeks exposure Laboratory Analyte Category Change (at least once) from Baseline Treatment Arm N Patients N Patients Fasting Triglycerides Increase by ≥50 mg/dL Olanzapine 745 39.6% 487 61.4% Placebo 402 26.1% NA a NA a Normal to High (<150 mg/dL to ≥200 mg/dL) Olanzapine 457 9.2% 293 32.4% Placebo 251 4.4% NA a NA a Borderline to High (≥150 mg/dL and <200 mg/dL to ≥200 mg/dL) Olanzapine 135 39.3% 75 70.7% Placebo 65 20.0% NA a NA a Fasting Total Cholesterol Increase by ≥40 mg/dL Olanzapine 745 21.6% 489 32.9% Placebo 402 9.5% NA a NA a Normal to High (<200 mg/dL to ≥240 mg/dL) Olanzapine 392 2.8% 283 14.8% Placebo 207 2.4% NA a NA a Borderline to High (≥200 mg/dL and <240 mg/dL to ≥240 mg/dL) Olanzapine 222 23.0% 125 55.2% Placebo 112 12.5% NA a NA a Fasting LDL Cholesterol Increase by ≥30 mg/dL Olanzapine 536 23.7% 483 39.8% Placebo 304 14.1% NA a NA a Normal to High (<100 mg/dL to ≥160 mg/dL) Olanzapine 154 0% 123 7.3% Placebo 82 1.2% NA a NA a Borderline to High (≥100 mg/dL and <160 mg/dL to ≥160 mg/dL) Olanzapine 302 10.6% 284 31.0% Placebo 173 8.1% NA a NA a a Not Applicable In phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), over a median exposure of 9.2 months, the mean increase in triglycerides in patients taking olanzapine was 40.5 mg/dL. In phase 1 of CATIE, the mean increase in total cholesterol was 9.4 mg/dL. Weight Gain Potential consequences of weight gain should be considered prior to starting olanzapine. Patients receiving olanzapine should receive regular monitoring of weight [see Patient Counseling Information ( 17 )] . Olanzapine Monotherapy in Adults In an analysis of 13 placebo-controlled olanzapine monotherapy studies, olanzapine-treated patients gained an average of 2.6 kg (5.7 lb) compared to an average 0.3 kg (0.6 lb) weight loss in placebo-treated patients with a median exposure of 6 weeks; 22.2% of olanzapine-treated patients gained at least 7% of their baseline weight, compared to 3% of placebo-treated patients, with a median exposure to event of 8 weeks; 4.2% of olanzapine-treated patients gained at least 15% of their baseline weight, compared to 0.3% of placebo-treated patients, with a median exposure to event of 12 weeks. Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Discontinuation due to weight gain occurred in 0.2% of olanzapine-treated patients and in 0% of placebo-treated patients. In long-term studies (at least 48 weeks), the mean weight gain was 5.6 kg (12.3 lb) (median exposure of 573 days, N=2021). The percentages of patients who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 64%, 32%, and 12%, respectively. Discontinuation due to weight gain occurred in 0.4% of olanzapine-treated patients following at least 48 weeks of exposure. Table 4 includes data on adult weight gain with olanzapine pooled from 86 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified. Table 4: Weight Gain with Olanzapine Use in Adults Amount Gained kg (lb) 6 Weeks (N=7465) (%) 6 Months (N=4162) (%) 12 Months (N=1345) (%) 24 Months (N=474) (%) 36 Months (N=147) (%) ≤0 26.2 24.3 20.8 23.2 17.0 0 to ≤5 (0-11 lb) 57.0 36.0 26.0 23.4 25.2 >5 to ≤10 (11-22 lb) 14.9 24.6 24.2 24.1 18.4 >10 to ≤15 (22-33 lb) 1.8 10.9 14.9 11.4 17.0 >15 to ≤20 (33-44 lb) 0.1 3.1 8.6 9.3 11.6 >20 to ≤25 (44-55 lb) 0 0.9 3.3 5.1 4.1 >25 to ≤30 (55-66 lb) 0 0.2 1.4 2.3 4.8 >30 (>66 lb) 0 0.1 0.8 1.2 2 Dose group differences with respect to weight gain have been observed. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, mean baseline to endpoint increase in weight (10 mg/day: 1.9 kg; 20 mg/day: 2.3 kg; 40 mg/day: 3 kg) was observed with significant differences between 10 vs 40 mg/day. 5.7 Tardive Dyskinesia Tardive dyskinesia (TD) is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic drugs, including WELTRUZA. TD can develop after a relatively brief treatment period at low dosages and may also occur after discontinuation of treatment. If antipsychotic treatment is discontinued, TD may partially or completely remit. Antipsychotic treatment, however, may suppress or partially suppress the signs and symptoms of TD, and may mask the underlying process. The effect that symptomatic suppression has upon the long-term course of TD is unknown. The TD risk appears to be highest among the elderly, especially elderly women, but it is not possible to predict which patients are likely to develop TD. The TD risk and the likelihood that TD will become irreversible increase with the duration of antipsychotic drug treatment and the cumulative dosage. Periodically reassess the need for continued treatment. If signs and symptoms of TD appear in WELTRUZA-treated patients, consider drug discontinuation. However, some patients may require WELTRUZA treatment despite the presence of TD. 5.8 Orthostatic Hypotension WELTRUZA may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, probably reflecting its α 1 -adrenergic antagonistic properties [see Patient Counseling Information ( 17 )] . From an analysis of the vital sign data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, orthostatic hypotension was recorded in ≥20% (1277/6030) of patients. Olanzapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (elderly patients, patients with dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. Caution is necessary in patients who receive treatment with other drugs having effects that can induce hypotension, bradycardia, respiratory or central nervous system depression [see Drug Interactions ( 7 )] . 5.9 Falls Antipsychotics, including WELTRUZA, may cause somnolence, postural hypotension, motor and sensory instability which may lead to falls and, consequently, fractures or other injuries. If patients have a condition or take concomitant drugs that could exacerbate these effects, complete fall risk assessments when initiating WELTRUZA treatment and recurrently for patients on long-term treatment. 5.10 Leukopenia, Neutropenia, and Agranulocytosis Class Effect In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including olanzapine. Agranulocytosis has also been reported. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of WELTRUZA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm 3 ) should discontinue WELTRUZA and have their WBC followed until recovery. 5.11 Dysphagia Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's disease. Olanzapine is not approved for the treatment of patients with Alzheimer's disease. 5.12 Seizures Like other antipsychotic drugs, WELTRUZA may cause seizures. This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold and WELTRUZA should be used cautiously. Conditions that lower the seizure threshold may be more prevalent in older patients. 5.13 Potential for Cognitive and Motor Impairment WELTRUZA, like other antipsychotics, may cause somnolence and has the potential to impair judgement, thinking, or motor skills. Somnolence was a commonly reported adverse reaction associated with oral olanzapine, occurring at an incidence of 26% in olanzapine patients compared to 15% in placebo patients. This adverse reaction was also dose related. Somnolence led to discontinuation in 0.4% (9/2500) of patients in the premarketing database. Since olanzapine has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that olanzapine therapy does not affect them adversely [see Patient Counseling Information ( 17 )] . 5.14 Body Temperature Regulation Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing WELTRUZA for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration [see Patient Counseling Information ( 17 )] . 5.15 Anticholinergic (antimuscarinic) Effects Olanzapine exhibits in vitro muscarinic receptor affinity [see Clinical Pharmacology ( 12.2 )] . In premarketing clinical trials with oral olanzapine, olanzapine was associated with constipation, dry mouth, and tachycardia, all adverse reactions possibly related to cholinergic antagonism. Such adverse reactions were not often the basis for discontinuations from olanzapine, but olanzapine should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, constipation, or a history of paralytic ileus or related conditions. In post marketing experience, the risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications [see Drug Interactions ( 7.1 )] . 5.16 Hyperprolactinemia As with other drugs that antagonize dopamine D 2 receptors, olanzapine elevates prolactin levels, and the elevation persists during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats [see Nonclinical Toxicology ( 13.1 )] . Published epidemiologic studies have shown inconsistent results when exploring the potential association between hyperprolactinemia and breast cancer. In placebo-controlled olanzapine clinical studies (up to 12 weeks), changes from normal to high in prolactin concentrations were observed in 30% of adults treated with olanzapine as compared to 10.5% of adults treated with placebo. In a pooled analysis from clinical studies including 8136 adults treated with olanzapine, potentially associated clinical manifestations included menstrual-related events (2% [49/3240] of females), sexual function-related events (2% [150/8136] of females and males), and breast-related events (0.7% [23/3240] of females, 0.2% [9/4896] of males). 5.17 Laboratory Tests Fasting blood glucose testing and lipid profile at the beginning of, and periodically during, treatment is recommended [see Warnings and Precautions ( 5.5 ) and Patient Counseling Information ( 17 )] .

warnings and cautions

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs for dementia-related psychosis, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the incidence of death in drug-treated patients was about 4.5%, compared to an incidence of about 2.6% in the placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. In placebo-controlled oral olanzapine clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively). WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Indications and Usage ( 1 )] .

warnings and cautions

5.4 Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue WELTRUZA and provide intensive symptomatic treatment and monitoring.

warnings and cautions

5.5 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with olanzapine exposure. DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. DRESS is sometimes fatal. Discontinue WELTRUZA if DRESS is suspected [see Patient Counseling Information ( 17 )] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 3 · 9 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Post-Injection Delirium/Sedation Syndrome [see Warnings and Precautions ( 5.2 )] Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions ( 5.3 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions ( 5.4 )] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions ( 5.5 )] Metabolic Changes [see Warnings and Precautions ( 5.6 )] Tardive Dyskinesia [see Warnings and Precautions ( 5.7 )] Orthostatic Hypotension [see Warnings and Precautions ( 5.8 )] Falls [see Warnings and Precautions ( 5.9 )] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions ( 5.10 )] Dysphagia [see Warnings and Precautions ( 5.11 )] Seizures [see Warnings and Precautions ( 5.12 )] Potential for Cognitive and Motor Impairment [see Warnings and Precautions ( 5.13 )] Body Temperature Regulation [see Warnings and Precautions ( 5.14 )] Anticholinergic (antimuscarinic) Effects [see Warnings and Precautions ( 5.15 )] Hyperprolactinemia [see Warnings and Precautions ( 5.16 )] Most common adverse reactions (≥5% in at least one of the treatment groups and greater than placebo) associated with WELTRUZA treatment: Weight increased, Somnolence, Headache, Constipation, and Injection Site Reactions (induration, pain, erythema, pruritus, swelling). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice. The safety of WELTRUZA for the treatment of schizophrenia in adults is based on adequate and well controlled studies of oral olanzapine in studies of patients with schizophrenia and other indications as well as in one 8-week placebo-controlled trial of WELTRUZA in adult patients with schizophrenia [see Clinical Studies ( 14 )]. The information below for WELTRUZA is derived primarily from a clinical trial database consisting of 849 patients receiving 3971 injections of WELTRUZA in 4 clinical trials. The majority of the safety data in this database is from a single phase 3 randomized, double-blind, placebo-controlled trial with an open-label, long-term safety phase conducted in patients with schizophrenia, with additional data from 3 open-label phase 1 trials, conducted in patients with schizophrenia or schizoaffective disorder. Additionally, data obtained from patients treated with oral olanzapine is also presented below. The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions listed elsewhere in labeling may not be repeated below. The entire label should be read to gain a complete understanding of the safety profile of WELTRUZA. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects during usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing healthcare provider with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied. Adverse Reactions Associated with Discontinuation of Trial in a Short-Term, Placebo-Controlled Period Overall, there was no meaningful difference in the incidence of discontinuation due to adverse reactions between WELTRUZA (5%; 23/500 patients) and placebo (4%; 6/167 patients) in an 8-week period. None of these Adverse Reactions occurred in >1% of patients. Commonly Observed Adverse Reactions in a Short-Term, Placebo-Controlled Trial The systemic safety profile of WELTRUZA was consistent with that of oral olanzapine. As such, injection site reactions (ISRs) are presented separately below, since they are specific to the injectable route of administration. In an 8-week placebo-controlled period, adverse reactions with an incidence of 5% or greater in at least one of the WELTRUZA treatment groups (318 mg, 425 mg, or 531 mg) and greater than placebo were: weight gain, injection site induration, injection site pain, injection site erythema, somnolence, headache, injection site pruritus, injection site swelling, and constipation. Adverse Reactions are presented in Table 5. Specific injection site reactions are presented in Table 6. Adverse Reactions Occurring at an Incidence of 2% or more among WELTRUZA-Treated Patients in a Short-Term, Placebo-Controlled Period of a Clinical Trial Table 5 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred in 2% or more of patients treated with WELTRUZA and with incidence greater than placebo who participated in the 8-week, placebo-controlled period. Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in ≥2% of patients in any WELTRUZA Group and Greater than Placebo Percentage of Patients Reporting Adverse Reaction Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Investigations Weight increased 9% 30% 39% 34% Waist circumference increased 1% 1% 2% 3% Nervous System Disorders Somnolence 2% 10% 6% 8% Headache 7% 6% 8% 4% Gastrointestinal disorders Constipation 4% 2% 5% 5% Dry mouth 1% 2% 3% 4% Dyspepsia 1% 4% 2% 1% Toothache 0% 2% 1% 1% Nausea 2% 2% 1% 1% Metabolism and nutrition disorders Increased appetite 2% 4% 2% 2% Respiratory, thoracic and mediastinal disorders Cough 0% 1% 1% 3% General disorders and administration site conditions Injection site reaction* 8% 26% 29% 31% Fatigue 1% 2% 2% 1% Musculoskeletal and connective tissue disorders Schizophrenia 0% 2% 0% 2% Anxiety 2% 2% 3% 1% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Dose Dependency of Adverse Reactions No dose dependency has been observed across WELTRUZA dose levels (corresponding to 10-20 mg/day oral olanzapine) for known olanzapine class effects. A dose group difference for oral olanzapine has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation for oral olanzapine [see Warnings and Precautions ( 5.5 , 5.15 )]. Injection Site Reactions During the 8-week double-blind, placebo-controlled period of the phase 3 trial, patients received two monthly injections of one of the WELTRUZA doses, or vehicle without active drug (placebo). Injection site reactions occurred in 29% of patients receiving WELTRUZA and in 8% of patients receiving placebo. Six patients (1.2%) who received WELTRUZA and none of the patients who received placebo were discontinued due to injection site reactions. The majority of injection site reactions were mild or moderate in severity and 0.7% of all injections resulted in a severe injection reaction. The most common injection site reactions (≥5% in any WELTRUZA group and higher than placebo) are presented in Table 6. Table 6: Injection Site Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA occurring in ≥5% in any WELTRUZA Group and Greater than Placebo Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Total WELTRUZA (N=500) Patients with at least 1 injection site reaction* 8% 26% 29% 31% 29% Injection site induration 3% 11% 14% 14% 13% Injection site pain 4% 9% 11% 10% 10% Injection site erythema 1% 7% 13% 9% 10% Injection site pruritus 1% 6% 5% 7% 6% Injection site swelling 1% 6% 6% 4% 5% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Less frequent ISRs (<5% and reported in at least 2 patients) reported throughout the phase 3 trial included: abscess, pustule, inflammation, irritation, edema, bruising, nodule, discharge, infection, and ulcer. Extrapyramidal Symptoms The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by reported adverse reactions during the placebo controlled 8-week period of a clinical trial comparing three WELTRUZA doses with placebo in the treatment of schizophrenia. Table 7: Extrapyramidal Syndrome (SMQ): Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA by Sub-SMQs, Preferred Term, and Treatment Group Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Akathisia (SMQ) 1% 1% 1% 2% Akathisia 1% 1% 1% 2% Psychomotor hyperactivity 0% 0% 0% 1% Restlessness 0% 1% 0% 0% Dyskinesia (SMQ) 0% 1% 0% 1% Dyskinesia 0% 1% 0% 0% Muscle twitching 0% 0% 0% 1% Dystonia (SMQ) 1% 1% 0% 1% Dystonia 1% 1% 0% 1% Muscle spasms 0% 0% 0% 1% Preferred terms are sorted by descending order of incidence within sub-SMQ category for the Total WELTRUZA group. Patients are counted only once in each preferred term category, and only once in each sub-SMQ category. MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standardized MedDRA query. Other Adverse Reactions Following is a list of treatment-emergent adverse reactions reported by patients treated with oral olanzapine (at multiple doses ≥1 mg/day) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients. Body as a Whole — Infrequent: chills, face edema, photosensitivity reaction, suicide attempt; Rare: chills and fever, hangover effect, sudden death. Cardiovascular System — Infrequent: cerebrovascular accident, vasodilatation. Digestive System — Infrequent: abdominal distension, nausea and vomiting, tongue edema; Rare: ileus, intestinal obstruction, liver fatty deposit. Hemic and Lymphatic System — Infrequent: thrombocytopenia. Metabolic and Nutritional Disorders — Frequent: alkaline phosphatase increased; Infrequent: bilirubinemia, hypoproteinemia. Musculoskeletal System — Rare: osteoporosis. Nervous System — Infrequent: ataxia, dysarthria, libido decreased, stupor; Rare: coma. Respiratory System — Infrequent: epistaxis; Rare: lung edema. Skin and Appendages — Infrequent: alopecia. Special Senses — Infrequent: abnormality of accommodation, dry eyes; Rare: mydriasis. Urogenital System — Infrequent: amenorrhea, breast pain, decreased menstruation, impotence, increased menstruation, menorrhagia, metrorrhagia, polyuria, urinary frequency, urinary retention, urinary urgency, urination impaired. Vital Signs and Laboratory Studies Vital Sign Changes Oral olanzapine was associated with orthostatic hypotension and tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and tachycardia in clinical trials [see Warnings and Precautions ( 5 )]. Laboratory Changes Olanzapine Monotherapy in Adults: An assessment of the premarketing experience for oral olanzapine revealed an association with asymptomatic increases in ALT, AST, and GGT. Within the original premarketing database of about 2400 adult patients with baseline ALT ≤90 IU/L, the incidence of ALT elevations to >200 IU/L was 2% (50/2381). None of these patients experienced jaundice or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued. In placebo-controlled oral olanzapine monotherapy studies in adults, clinically significant ALT elevations (change from <3 times the upper limit of normal [ULN] at baseline to ≥3 times ULN) were observed in 5% (77/1426) of patients exposed to olanzapine compared to 1% (10/1187) of patients exposed to placebo. ALT elevations ≥5 times ULN were observed in 2% (29/1438) of olanzapine-treated patients, compared to 0.3% (4/1196) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No patient with elevated ALT values experienced jaundice, liver failure, or met the criteria for Hy’s Rule. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, high GGT levels were recorded in ≥1% (88/5245) of patients. Caution should be exercised in patients with signs and symptoms of hepatic impairment, in patients with pre­-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. Oral olanzapine administration was also associated with increases in serum prolactin [see Warnings and Precautions ( 5.16 )] , with an asymptomatic elevation of the eosinophil count in 0.3% of patients, and with an increase in CPK. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, elevated uric acid was recorded in ≥3% (171/4641) of patients. ECG Changes In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between oral olanzapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc (Fridericia corrected), and PR intervals. Oral olanzapine use was associated with a mean increase in heart rate compared to placebo in adults (+2.4 beats per minute vs no change with placebo). This increase in heart rate may be related to olanzapine’s potential for inducing orthostatic changes [see Warnings and Precautions ( 5.8 )] . 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of oral olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to oral olanzapine therapy and include the following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), cholestatic or mixed liver injury, diabetic coma, diabetic ketoacidosis, discontinuation reaction (diaphoresis, nausea or vomiting), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hepatitis, jaundice, neutropenia, pancreatitis, priapism, rash, restless legs syndrome, rhabdomyolysis, salivary hypersecretion, stuttering, and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been reported.

adverse reactions

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice. The safety of WELTRUZA for the treatment of schizophrenia in adults is based on adequate and well controlled studies of oral olanzapine in studies of patients with schizophrenia and other indications as well as in one 8-week placebo-controlled trial of WELTRUZA in adult patients with schizophrenia [see Clinical Studies ( 14 )]. The information below for WELTRUZA is derived primarily from a clinical trial database consisting of 849 patients receiving 3971 injections of WELTRUZA in 4 clinical trials. The majority of the safety data in this database is from a single phase 3 randomized, double-blind, placebo-controlled trial with an open-label, long-term safety phase conducted in patients with schizophrenia, with additional data from 3 open-label phase 1 trials, conducted in patients with schizophrenia or schizoaffective disorder. Additionally, data obtained from patients treated with oral olanzapine is also presented below. The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions listed elsewhere in labeling may not be repeated below. The entire label should be read to gain a complete understanding of the safety profile of WELTRUZA. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects during usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing healthcare provider with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied. Adverse Reactions Associated with Discontinuation of Trial in a Short-Term, Placebo-Controlled Period Overall, there was no meaningful difference in the incidence of discontinuation due to adverse reactions between WELTRUZA (5%; 23/500 patients) and placebo (4%; 6/167 patients) in an 8-week period. None of these Adverse Reactions occurred in >1% of patients. Commonly Observed Adverse Reactions in a Short-Term, Placebo-Controlled Trial The systemic safety profile of WELTRUZA was consistent with that of oral olanzapine. As such, injection site reactions (ISRs) are presented separately below, since they are specific to the injectable route of administration. In an 8-week placebo-controlled period, adverse reactions with an incidence of 5% or greater in at least one of the WELTRUZA treatment groups (318 mg, 425 mg, or 531 mg) and greater than placebo were: weight gain, injection site induration, injection site pain, injection site erythema, somnolence, headache, injection site pruritus, injection site swelling, and constipation. Adverse Reactions are presented in Table 5. Specific injection site reactions are presented in Table 6. Adverse Reactions Occurring at an Incidence of 2% or more among WELTRUZA-Treated Patients in a Short-Term, Placebo-Controlled Period of a Clinical Trial Table 5 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred in 2% or more of patients treated with WELTRUZA and with incidence greater than placebo who participated in the 8-week, placebo-controlled period. Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in ≥2% of patients in any WELTRUZA Group and Greater than Placebo Percentage of Patients Reporting Adverse Reaction Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Investigations Weight increased 9% 30% 39% 34% Waist circumference increased 1% 1% 2% 3% Nervous System Disorders Somnolence 2% 10% 6% 8% Headache 7% 6% 8% 4% Gastrointestinal disorders Constipation 4% 2% 5% 5% Dry mouth 1% 2% 3% 4% Dyspepsia 1% 4% 2% 1% Toothache 0% 2% 1% 1% Nausea 2% 2% 1% 1% Metabolism and nutrition disorders Increased appetite 2% 4% 2% 2% Respiratory, thoracic and mediastinal disorders Cough 0% 1% 1% 3% General disorders and administration site conditions Injection site reaction* 8% 26% 29% 31% Fatigue 1% 2% 2% 1% Musculoskeletal and connective tissue disorders Schizophrenia 0% 2% 0% 2% Anxiety 2% 2% 3% 1% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Dose Dependency of Adverse Reactions No dose dependency has been observed across WELTRUZA dose levels (corresponding to 10-20 mg/day oral olanzapine) for known olanzapine class effects. A dose group difference for oral olanzapine has been observed for fatigue, dizziness, weight gain and prolactin elevation. In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of fatigue (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) was observed with significant differences between 10 vs 40 and 20 vs 40 mg/day. The incidence of dizziness (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) was observed with significant differences between 20 vs 40 mg. Dose group differences were also noted for weight gain and prolactin elevation for oral olanzapine [see Warnings and Precautions ( 5.5 , 5.15 )]. Injection Site Reactions During the 8-week double-blind, placebo-controlled period of the phase 3 trial, patients received two monthly injections of one of the WELTRUZA doses, or vehicle without active drug (placebo). Injection site reactions occurred in 29% of patients receiving WELTRUZA and in 8% of patients receiving placebo. Six patients (1.2%) who received WELTRUZA and none of the patients who received placebo were discontinued due to injection site reactions. The majority of injection site reactions were mild or moderate in severity and 0.7% of all injections resulted in a severe injection reaction. The most common injection site reactions (≥5% in any WELTRUZA group and higher than placebo) are presented in Table 6. Table 6: Injection Site Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA occurring in ≥5% in any WELTRUZA Group and Greater than Placebo Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Total WELTRUZA (N=500) Patients with at least 1 injection site reaction* 8% 26% 29% 31% 29% Injection site induration 3% 11% 14% 14% 13% Injection site pain 4% 9% 11% 10% 10% Injection site erythema 1% 7% 13% 9% 10% Injection site pruritus 1% 6% 5% 7% 6% Injection site swelling 1% 6% 6% 4% 5% * Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer. Less frequent ISRs (<5% and reported in at least 2 patients) reported throughout the phase 3 trial included: abscess, pustule, inflammation, irritation, edema, bruising, nodule, discharge, infection, and ulcer. Extrapyramidal Symptoms The following table enumerates the percentage of patients with treatment-emergent extrapyramidal symptoms as assessed by reported adverse reactions during the placebo controlled 8-week period of a clinical trial comparing three WELTRUZA doses with placebo in the treatment of schizophrenia. Table 7: Extrapyramidal Syndrome (SMQ): Incidence in a Short-Term, Placebo-Controlled Period of a Clinical Trial with WELTRUZA by Sub-SMQs, Preferred Term, and Treatment Group Placebo (N=167) WELTRUZA 318mg (N=163) WELTRUZA 425mg (N=168) WELTRUZA 531mg (N=169) Akathisia (SMQ) 1% 1% 1% 2% Akathisia 1% 1% 1% 2% Psychomotor hyperactivity 0% 0% 0% 1% Restlessness 0% 1% 0% 0% Dyskinesia (SMQ) 0% 1% 0% 1% Dyskinesia 0% 1% 0% 0% Muscle twitching 0% 0% 0% 1% Dystonia (SMQ) 1% 1% 0% 1% Dystonia 1% 1% 0% 1% Muscle spasms 0% 0% 0% 1% Preferred terms are sorted by descending order of incidence within sub-SMQ category for the Total WELTRUZA group. Patients are counted only once in each preferred term category, and only once in each sub-SMQ category. MedDRA=Medical Dictionary for Regulatory Activities; SMQ=standardized MedDRA query. Other Adverse Reactions Following is a list of treatment-emergent adverse reactions reported by patients treated with oral olanzapine (at multiple doses ≥1 mg/day) in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo. Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients. Body as a Whole — Infrequent: chills, face edema, photosensitivity reaction, suicide attempt; Rare: chills and fever, hangover effect, sudden death. Cardiovascular System — Infrequent: cerebrovascular accident, vasodilatation. Digestive System — Infrequent: abdominal distension, nausea and vomiting, tongue edema; Rare: ileus, intestinal obstruction, liver fatty deposit. Hemic and Lymphatic System — Infrequent: thrombocytopenia. Metabolic and Nutritional Disorders — Frequent: alkaline phosphatase increased; Infrequent: bilirubinemia, hypoproteinemia. Musculoskeletal System — Rare: osteoporosis. Nervous System — Infrequent: ataxia, dysarthria, libido decreased, stupor; Rare: coma. Respiratory System — Infrequent: epistaxis; Rare: lung edema. Skin and Appendages — Infrequent: alopecia. Special Senses — Infrequent: abnormality of accommodation, dry eyes; Rare: mydriasis. Urogenital System — Infrequent: amenorrhea, breast pain, decreased menstruation, impotence, increased menstruation, menorrhagia, metrorrhagia, polyuria, urinary frequency, urinary retention, urinary urgency, urination impaired. Vital Signs and Laboratory Studies Vital Sign Changes Oral olanzapine was associated with orthostatic hypotension and tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and tachycardia in clinical trials [see Warnings and Precautions ( 5 )]. Laboratory Changes Olanzapine Monotherapy in Adults: An assessment of the premarketing experience for oral olanzapine revealed an association with asymptomatic increases in ALT, AST, and GGT. Within the original premarketing database of about 2400 adult patients with baseline ALT ≤90 IU/L, the incidence of ALT elevations to >200 IU/L was 2% (50/2381). None of these patients experienced jaundice or other symptoms attributable to liver impairment and most had transient changes that tended to normalize while olanzapine treatment was continued. In placebo-controlled oral olanzapine monotherapy studies in adults, clinically significant ALT elevations (change from <3 times the upper limit of normal [ULN] at baseline to ≥3 times ULN) were observed in 5% (77/1426) of patients exposed to olanzapine compared to 1% (10/1187) of patients exposed to placebo. ALT elevations ≥5 times ULN were observed in 2% (29/1438) of olanzapine-treated patients, compared to 0.3% (4/1196) of placebo-treated patients. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine or discontinued olanzapine. No patient with elevated ALT values experienced jaundice, liver failure, or met the criteria for Hy’s Rule. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, high GGT levels were recorded in ≥1% (88/5245) of patients. Caution should be exercised in patients with signs and symptoms of hepatic impairment, in patients with pre­-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. Oral olanzapine administration was also associated with increases in serum prolactin [see Warnings and Precautions ( 5.16 )] , with an asymptomatic elevation of the eosinophil count in 0.3% of patients, and with an increase in CPK. From an analysis of the laboratory data in an integrated database of 41 completed clinical studies in adult patients treated with oral olanzapine, elevated uric acid was recorded in ≥3% (171/4641) of patients. ECG Changes In pooled studies of adults as well as pooled studies of adolescents, there were no significant differences between oral olanzapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc (Fridericia corrected), and PR intervals. Oral olanzapine use was associated with a mean increase in heart rate compared to placebo in adults (+2.4 beats per minute vs no change with placebo). This increase in heart rate may be related to olanzapine’s potential for inducing orthostatic changes [see Warnings and Precautions ( 5.8 )] .

adverse reactions

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of oral olanzapine. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure. Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to oral olanzapine therapy and include the following: allergic reaction (e.g., anaphylactoid reaction, angioedema, pruritus or urticaria), cholestatic or mixed liver injury, diabetic coma, diabetic ketoacidosis, discontinuation reaction (diaphoresis, nausea or vomiting), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hepatitis, jaundice, neutropenia, pancreatitis, priapism, rash, restless legs syndrome, rhabdomyolysis, salivary hypersecretion, stuttering, and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been reported.

adverse reactions table

<table width="800px" cellspacing="0" cellpadding="5"> <caption>Table 5: Adverse Reactions: Incidence in a Short-Term, Placebo-Controlled Period of a clinical trial occurring in &#x2265;2% of patients in any WELTRUZA Group and Greater than Placebo </caption> <col width="211.9pt"/> <col width="255.3pt"/> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/> <td align="center" colspan="4" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Percentage of Patients Reporting Adverse Reaction</content> </paragraph> </td> </tr> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Placebo </content> <content styleCode="bold">(N=167)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 318mg </content> <content styleCode="bold">(N=163)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 425mg </content> <content styleCode="bold">(N=168)</content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">WELTRUZA 531mg </content> <content styleCode="bold">(N=169)</content> </paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Investigations</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Weight increased</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>9%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>30%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>39%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>34%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Waist circumference increased</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Somnolence</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>10%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>6%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>7%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>6%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Gastrointestinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Constipation</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>5%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Dry mouth</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Dyspepsia</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Toothache</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Nausea</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Metabolism and nutrition disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Increased appetite</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>4%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Cough</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">General disorders and administration site conditions</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Injection site reaction* </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>8%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>26%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>29%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>31%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Fatigue</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Schizophrenia</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>0%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>Anxiety</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>2%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>3%</paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>1%</paragraph> </td> </tr> <tr> <td colspan="5"> <content styleCode="italics">*</content> Injection-site reaction is a composite term that includes injection-site abscess, bruising, discharge, discomfort, edema, erythema, hematoma, induration, infection, inflammation, injury, irritation, nodule, pain, pruritus, pustule, swelling, and ulcer.</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.